Systematic review of antifibrotic effects of metformin: Insights from preclinical and clinical studies and potential relevance to oral submucous fibrosis
Abstract
Fibrosis involves excessive deposition of extracellular matrix, leading to ongoing tissue remodeling and organ failure. Metformin, a common antidiabetic medication, has shown potential antifibrotic effects by affecting AMP-activated protein kinase (AMPK) and transforming growth factor-beta (TGF-β) signaling pathways. This systematic review aimed to synthesize the current evidence on the antifibrotic effects of metformin and to explore its potential translational relevance to oral submucous fibrosis (OSF). The review was conducted in accordance with the PRISMA 2020 guidelines and prospectively registered with PROSPERO (CRD42024531382). A total of 29 studies were included, comprising 3 randomized controlled trials, 1 observational cohort study, 11 in vivo studies, 4 in vitro studies, and 10 combined in vitro/in vivo investigations. The included studies evaluated the effects of metformin on fibrosis-related outcomes across multiple organ systems. No studies directly investigating metformin in OSF were identified; therefore, its potential relevance to OSF was inferred from shared molecular and pathogenic mechanisms underlying fibrogenesis. Metformin demonstrated consistent antifibrotic activity across multiple experimental models, primarily mediated through activation of AMP-activated protein kinase (AMPK), inhibition of TGF-β/ Smad signaling, modulation of mTOR pathways, and attenuation of oxidative stress and inflammatory responses. Emerging experimental evidence, not directly…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.